FENNEC PHARMACEUTICALS INC. (FENC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 7M 14M 21M Q3 '24: 7M Q4 '24: 7.9M Q1 '25: 8.8M Q2 '25: 9.7M Q3 '25: 12.5M Q4 '25: 13.8M Q1 '26: 15.1M Q2 '26: 17.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 3.5M 7M 10.5M Q1 '23: 1.6M Q2 '23: 3.2M Q3 '23: 6.2M Q4 '23: 9.1M Q1 '23 Q2 '23 Q3 '23 Q4 '23

Operating Income Quarterly

-6M -4M -2M 0 2M 4M 6M Q3 '24: -5.2M Q4 '24: -934K Q1 '25: -808K Q2 '25: -2.7M Q3 '25: -189K Q4 '25: -2.6M Q1 '26: -119K Q2 '26: 1.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-6M -4M -2M 0 2M 4M 6M Q3 '24: -5.7M Q4 '24: -2M Q1 '25: -1.2M Q2 '25: -3.2M Q3 '25: -638K Q4 '25: -4.8M Q1 '26: 201K Q2 '26: 2M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 250K 500K 750K Q1 '23: 95K Q2 '23: 148K Q3 '23: 331K Q4 '23: 685K Q1 '23 Q2 '23 Q3 '23 Q4 '23

Operating Cash Flow Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '24: -2.2M Q4 '24: -1.5M Q1 '25: -4.3M Q2 '25: -3.7M Q3 '25: 1.5M Q4 '25: -6M Q1 '26: 2.4M Q2 '26: 50K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q4 '12: -557K Q1 '13: -407K Q2 '13: -889K Q3 '13: -469K Q4 '13: -445K Q1 '14: -378K Q2 '14: -410K Q3 '14: -443K Q4 '12 Q1 '13 Q2 '13 Q3 '13 Q4 '13 Q1 '14 Q2 '14 Q3 '14

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '24: 31.1M Q2 '24: 27.3M Q3 '24: 27.4M Q1 '25: 27.6M Q2 '25: 27.7M Q3 '25: 27.9M Q1 '26: 35.5M Q2 '26: 36.4M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.60 -0.40 -0.20 0.00 0.20 0.40 0.60 Q3 '24: -0.13 Q4 '24: -0.02 Q1 '25: -0.47 Q2 '25: -0.38 Q3 '25: -0.19 Q4 '25: -0.33 Q1 '26: -0.28 Q2 '26: -0.12 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.